CID755673 is a potent and selective cell-active small molecule inhibitor for PKD with an IC50 of 182 nM; exhibits selective PKD1 inhibition when compared with AKT, PLK1, CAK, CAMKIIα, and PKC isoforms.

CID888706 is a small molecule, pan activator of Rho-family GTPases..

CIDD 0067106 is a novel natural product-based diaryloxazole that potent and selective antiproliferative activities against androgen receptor-positive breast cancer cells (MDA-MB-453 cell GI50=0.8 uM).

Cilastatin is an inhibitor of dipeptidase (dehydropeptidase I), a renal dipeptidase.

Cilazapril Monohydrate is a angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and congestive heart failure.

Ciliobrevin D is a cell-permeable, reversible, specific inhibitor of cytoplasmic dynein, blocks dynein-dependent microtubule gliding and ATPase activity while sparing kinesin dependent cellular trafficking.

Cilomilast(SB 207499; Ariflo) is a potent PDE4 inhibitor with IC50 of about 110 nM, has anti-inflammatory activity and low central nervous system activity.

Ciluprevir (BILN2061) is a potent HCV NS3/4A protease inhibitor with Ki of 0.66 and 0.30 nM for NS3-NS4A protease of HCV 1b and HCV 1a, respectively.

Cimiside B, a glycoside alkaloid, isolated from the rhizome of Cimicifuga dahurica.

Cinchonine is a natural compound present in Cinchona bark. Cinchonine activates endoplasmic reticulum stress-induced apoptosis in human liver cancer cells.

Cinnarizine is a medication derivative of piperazine, and characterized as an antihistamine and a calcium channel blocker.

Cipemastat (Ro 32-3555) is a potent, second-generation, orally active MMP inhibitor, preferentially inhibits collagenases (MMP-1, -8, and -13) and gelatinase B (MMP-9).

Ciprofibrate is a peroxisome proliferator-activated receptor agonist.

Ciprofloxacin (Bay-09867) is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.

Ciproxifan maleate(FUB-359 maleate) is a highly potent and selective histamin H3-receptor antagonist with IC50 of 9.2 nM, with low apparent affinity at other receptor subtypes.

Cirsimaritin binds weakly to the benzodiazepine site on GABAA receptors, with antidepressant, anxiolytic and antinociceptive activities.

cis Ned-19 is the stereoisomer of trans Ned-19, a chemical probe for the Ca(2+)-releasing second messenger NAADP.

Cisatracurium Besylate is a nondepolarizing neuromuscular blocking agent, antagonizing the action of acetylcholine by inhibiting neuromuscular transmission.

CJ-13610 is a potent 5-Lipoxygenase (5-LO) inhibitor that suppresses 5-LO product formation with IC50 of 70 nM.

CK 666 (CK 0944666) is a small molecule Arp2/3 complex inhibitor with IC50 of 4 uM, inhibits actin polymerization with either BtArp2/3 complex (IC50=17 uM) or SpArp2/3 complex (IC50=5 uM).

CK1-IN-3c is a novel casein kinase 1δ/ε (CK1δ/ε) inhibitor with IC50 of 1.6 uM.

CK2-IN-1 is a potent, competitive inhibitor of ATP binding to Casein kinase 2(CK2) with IC50 of 9 nM, induces differentiation of epidermal progenitor cells to terminally differentiated keratinocytes with EC50 of 0.1 uM..

CKD-516 (Valecobulin, CKD516) is a potent beta-tubulin polymerization inhibitor with marked antitumor activity both in vitro and in vivo.

CKD-519 (Rocacetrapib, CKD519) is a potent, selective cholesteryl ester transfer protein (CETP) inhibitor, inhibits the CETP-mediated transfer of cholesteryl ester in human serum with IC50 of 2.3 nM.

CL 316243 (BTA 243) is a potent, highly selective, orally active β3-adrenoceptor agonist with EC50 of 3 nM.

CL 316243 is a potent, highly selective, orally active β3-adrenoceptor agonist with EC50 of 3 nM.

CL-82198 is a potent, selective inhibitor of MMP-13 (89% inhibition at 10 ug/mL), displays no activity at MMP-1, MMP-9 and TACE, significantly reduces the migration of LS174 cells by 55% at 10 uM..

Cladribine (Leustatin, Litak, 2CDA) is an adenosine deaminase inhibitor for U266, RPMI8226, and MM1.S cells with IC50 of approximately 2.43 μM, 0.75 μM, and 0.18 μM, respectively.

Cl-amidine (hydrochloride) is a peptidylarginine deminase (PAD) inhibitor, with an IC50 5.9 μM for PAD4.

Clanfenur is a substituted benzoylphenylurea and an analogue of the pesticide diflubenzuron with potential antineoplastic activity.

Clarithromycin is a macrolide antibiotic and a CYP3A4 inhibitor.

Class I and IIB HDAC inhibitor 42 is a novel potent, selective class I and IIB inhibitor (HDAC1 Ki=0.27 nM) for topical treatment of cutaneous t-cell lymphoma..

Clinofibrate (S-8527) is a hypelipidemic agent and a HMG-CoA reductase inhibitor.

Clioquinol is an orally bioavailable, lipophilic, copper-binding, halogenated 8-hydroxyquinoline with antifungal, antiparasitic and potential antitumor activities.

CLK inhibitor T3 (T3) is a highly potent, selective, and cell-based stable CDC-like kinase (CLK) inhibitor with 0.67, 15 and 110 nM for CLK1,2 and 3, respectively.

CLK2 inhibitor Indazole1 is a novel potent, selective inhibitor of CLK2 with IC50 of 2.7 nM, 60-fold selectivity over PKA and >600-fold selectivity over a panel of 34 kinases.

Clobenpropit (VUF-9153) is a highly potent histamine H3 antagonist/inverse agonist with pA2 value of 9.93, also displays partial agonist activity at H4 receptors.

Clobenpropit (VUF-9153) is a highly potent histamine H3 antagonist/inverse agonist with pA2 value of 9.93, also displays partial agonist activity at H4 receptors.

Clocapramine hydrochloride hydrate is an antagonist of the D2 and 5-HT2A receptors.

Clofentezine, a growth inhibitor, has sublethal effects on life-table parameters of Tetranychus urticae Koch females.

Clopidogrel (Plavix) is an oral, thienopyridine class antiplatelet agent.

Cloquintocet-mexyl is a herbicide, used to control coarse annual grass of the family poaceae (gramineae).

Clozapine N-oxide is a major metabolite of Clozapine noted to decrease SR-2A (5-HT2 serotonin receptor) density in vitro.

CLP290 (CLP-290) is an orally acirtve small molecule K+-Cl- cotransporter isotype 2 (KCC2) activator, the carbamate prodrug of CLP257; In vivo co-treatment with morphine and oral CLP290 prevented membrane KCC2 downregulation in SDH neurons. Concurrently, co-treatment with CLP290 significantly mitigated MIH and acute administration of CLP257 in established MIH restored normal nociceptive behavior.

ClpP inhibitor M21 is a noncompetitive inhibitor of ClpP with IC50 of 41.42 uM, inhibits ClpP cleavage of SUc-LY-AMC substrate in a peptidase assay.

CLSP37 (RIPK2 inhibitor CLSP37) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 16.3 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling.

CLSP43 (RIPK2 inhibitor CLSP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling.

CM03 is a G-quadruplex-binding compound that potently inhibits cell growth in PDAC cell lines (MIA PaCa-2 IC50=19 nM).

CM-675 (CM675) is a potent, dual PDE5 and classI-HDAC inhibitor with IC50 of 114/673 nM for PDE5A/HDAC1, respectively.

CMA-008 is a cell-permeable, small molecule modulator of NAADP-mediated Ca2+ release, competes with NAADP binding, inhibit Ca2+ release via the NAADP receptor (IC50=15 uM-1 mM).

CMC2.24 (TRB-N0224) is a novel tricarbonylmethane agent that inhibits the Ras-RAF-MEK-ERK pathway, inhibits Ras activation in pancreatic cancer both in vitro and in vivo.

c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

CMK is a RSK2 kinase inhibitor.

CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival, without effect on normal B cells.

CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival, without effect on normal B cells.

CMPD167 (MRK-1) is an orally acitve small molecule that binds to CCR5 to inhibit gp120 association, inhibits different stages of the virus-cell attachment and entry process (CCR5-using virus SHIV-162P3, IC50<1 nM)..

CMPDA is a potent positive allosteric modulator of GluR2 receptors with EC50 of 45.4 and 63.4 nM at GluR2i and GluR2o respectively, in a calcium influx screening assays.

CN750 (CN-750) is novel BRD4 (BD1, 2) inhibitor with IC50 of 44 nM, MV4-11 IC50 of 0.54 uM.

CNP-AFU (2-Chloro-4-nitrophenyl α-L-fucopyranoside) is a substrate for alpha-L-fucosidase(AFU).

CNS 7056 is a new short-acting sedative/anaesthetic that acts on GABAA receptors in the brain.

CN-SAH is a potent and selective inhibitor of histone methyl transferase DOT1L with IC50 of 26 nM, displays >10-fold selectivity over DNMT1, PRMT3, PRMT5, and G9α..

CNT2 inhibitor-1 is a potent concentrative nucleoside transporter 2 Inhibitor (CNT2), with an IC50 of 640 nM for hCNT2.

CNV1014802 (GSK-1014802, Raxatrigine, Vixotrigine, BIIB074) is a potent, selective Nav1.7 sodium channel blocker, shows analgesic effects and potential in the treatment of cognitive symptoms of schizophrenia in vivo.

CNX-1351 is a selective covalent Inhibitor of PI3Kα. CNX-1351 was tested against all four of the class I PI3K enzymes α, β, γ, and δ.

CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.

Cobimetinib racemate is the racemate form of Cobimetinib (GDC-0973, XL518), which is a potent, highly selective inhibitor of MEK1/2..

Cobimetinib R-enantiomer (GDC-0973.

Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection..

COH29 is a potent ribonucleotide reductase (RNR) inhibitor with anticancer activity with an IC50 of 8 μM in KB cell.

COH-SR4 (Mitochondria uncoupler SR4) is a bonafide uncoupler that induces energetic stress on cells, consequently leading to AMPK activation and mTOR inhibition without any effects on ERK/MEK MAPK signaling.

Col 003 is a small-molecule compound that inhibits the interaction of Hsp47 with collagen with IC50 of 1.8 uM, binds to the collagen-binding site on Hsp47.

Collagen proline hydroxylase inhibitor is a collagen proline hydroxylase inhibitor; useful for antifibroproliferative agents.

Combretastatin A1 diphosphate OXi4503 is the diphosphate prodrug of the stilbenoid combretastatin A1, originally isolated from the plant Combretum caffrum, with vascular-disrupting and antineoplastic activities.

Compound 101 (GRK2 inhibitor 101, Takeda compound 101, Cmpd101) is a novel membrane-permeable, small-molecule inhibitor of GRK2 and GRK3.

Compound 3-110-22 is a small molecule that inhibits dengue virus (DENV) by binding to its envelope protein E.

Compound 621433144 (ZINC000621433144, Z3269026405) is a potent, selective full agonist of the D4 receptor with 2,500-fold subtype selectivity.

Compound 7004 (IRAK2 mimetic 7004) is a small molecule mimetic of a-helical domain of IRAK2, inhibit IL-33–induced NF-κB transcriptional activity (IC50=9.7 uM) by disrupting Myddosome formation.

Compound 919278 is a specific inhibitor of lymphotoxin β receptor (LTβR, IC50=0.169 uM), and TNF receptor superfamily member 12A (FN14)-dependent nuclear translocation of p52 (IC50=0.167 uM) via inhibiting CDK12/CCNK, does not inhibit the TNF-α-mediated nuclear translocation of p65 (RelA).

Contezolid (MRX I) is an orally active oxazolidinone agent with antibacterial activity Gram-positive pathogens, including MRSA, penicillin-PRSP, PISP, and vancomycin-resistant enterococci (VRE) with MIC of 0.25-4 ug/mL.

Contilisant is a neuroprotective, non-toxic, antioxidant, permeable ligand, showing in vitro pharmacological properties on the selected biological targets (hAChE IC50=0.53 uM.

Corin is a dual inhibitor of histone lysine specific demethylase (LSD1) and histone deacetylase (HDAC), with a Ki(inact) of 110 nM for LSD1 and an IC50 of 147 nM for HDAC1.

corticotropin releasing factor (CRF) antagonist.

Corticotropin-releasing hormone (CRH) is a peptide hormone involved in the stress response..

Cortisone acetate (Cortisone 21-acetate) is a synthetic glucocorticoid corticosteroid and corticosteroid ester.

Cortisone is a pregnane (21-carbon) steroid hormone, one of the main hormones released by the adrenal gland in response to stress.

Cortodoxone is a glucocorticoid steroid hormone that can be oxygenated to cortisol (Hydrocortisone).

Cot inhibitor-1 is a COT/Tpl2 inhibitor.

Cot inhibitor-2 is a COT/Tpl2 inhibitor.

Cotylimide-VI (CTL-VI) is a small molecule that perturbs plant hormone strigolactone accumulation and inhibits hypocotyl growth..

Coumestrol, a phytoestrogen present in soybean products, exhibits activities against cancers, neurological disorders, and autoimmune diseases. It suppresses proliferation of ES2 cells with an IC50 of 50 μM.

Cowanin is a novel natural product from Garcinia speciosa that inhibits the Notch signaling pathway with IC50 of 2.4 uM.

CP 465022 hydrochloride is a selective GluR (AMPA) antagonist which is non-competitive.

CP-31398 is a small molecule p53 reactivator that protects p53 from thermal denaturation, not only reactivates mutant p53 but also induces stabilization of wild type p53.

CP-339818 is a potent, selective, non-peptide KV1.3 channel antagonist with IC50 of 200 nM.

CP-481715 is a potent and selective CCR1 antagonist with Ki of 9.2 nM and IC50 of 74 nM, lacks intrinsic agonist activity and .

CP-547632 is as a potent inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases (IC50 11 and 9 nM, respectively).

CP-724,714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc. Phase 2.

CP-724714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc in cell-free assays. Phase 2.

CP-809101 Hcl is a potent and selective 5-HT2C receptor agonist with pEC50 of 9.96/7.19/6.81 for human 5-HT2C/5-HT2B/5-HT2A receptors respectively.

CPA inhibitor is a potent inhibitor for carboxypeptidase A (CPA).

CPG-52364 (CPG52364) is an orally available, small molecule TLR7/8/9 antagonist for the treatment of systemic lupus erythematosus and other autoimmune disorders..

CPI 0610 is a potent, selective, and cell-active BET bromodomain inhibitor with IC50 of 39 nM for BRD4-BD1 in TR-FRET assay.

CPI-360 is a compound in design and preparation of wew palladium precatalysts for C-C and C-N cross-coupling reactions.

CPI-444 is an orally administered antagonist of the adenosine A2A receptor. It is designed to block the action of adenosine that is produced by tumors.

CPI644 is a potent, selective, cell-active CBP/EP300 bromodomain inhibitor with IC50 of 0.18 uM for CBP.

CPP-115 is an orally available, small molecule, next-generation GABA aminotransferase (GABA-AT) inhibitor with Ki of 31 uM, without other GABAergic or off-target activities.

CPSI-1306 (CPSI1306) is an orally available small-molecule MIF antagonist, protects against UVB-induced squamous cell carcinoma, reduces the severity of animal model of multiple sclerosis..

CPT157633 is a novel potent, selective PTP1B inhibitor with Ki of 40 nM, shows markedly less activities against a panel of 6 PTPs and 2 dual-specificity phosphatases.

CPTH2 is a specific histone acetyltransferase inhibitor modulating Gcn5 network in vitro and in vivo, inhibits H3 acetylation and induces cell-cycle perturbation and apoptosis in U-937 cells.

CPTH6 hydrobromide is a thiazole derivative that can reduce histone acetylation and histone acetyltransferase (HAT) activity in human leukemia cells, CPTH6 is a specific Gcn5/pCAF inhibitor.

CPTH6 is a thiazole derivative that can reduce histone acetylation and histone acetyltransferase (HAT) activity in human leukemia cells, CPTH6 is a specific Gcn5/pCAF inhibitor.

CPYPP is a small-molecule inhibitor of the Rac activator DOCK2 with IC50 of 22.8 uM (DOCK2DHR-2-mediated Rac GEF activity), inhibits DOCK2-Rac1 interaction.

CR4056 (CR 4056, CR-4056) is a novel, orally active imidazoline-2 receptor (I2R) ligand with binding IC50 of 596 nM, also selectively inhibits the enzymatic activity of MAO-A with IC50 of 202.7 nM; increases norepinephrine (NE) tissue levels both in the rat cerebral cortex and lumbar spinal cord, shows ED50 of 5.8 mg/kg in CFA rat model of inflammatory pain; shows high effectivity against bortezomib-induced painful neuropathy in rats.

CR6086 (CR-6086) is a potent, selective prostaglandin E2 receptor 4 (EP4) antagonist with Ki of 16.6 nM (hEP4 receptor), inhibits PGE2-stimulated cAMP production with IC50 of 22 nM.

Difelikefalin (CR-845; FE-202845) is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease[1][2].

Crebinostat is a novel cognitive enhancer that inhibits class I HDAC/1/2/3 (IC50=0.7/1.0/2.0 nM), class IIb HDAC6 (IC50=9.3 nM) with weaker inhibition of the class I HDAC8 and no significant inhibition of the class IIa HDAC/4/5/7/9; potently induces acetylation of both histone H3 and histone H4 as well as enhanced the expression of the CREB target gene Egr1 in cultured mouse primary neurons; upregulates Bdnf and Grn, and downregulates Mapt (tau) gene expression-genes; brain penetrant.

cRIPGBM (RIPGBM derivative cRIPGBM, RIPGBM-18) is a metabolite of RIPGBM induces apoptosis in GBM CSCs (EC50=68 nM in GBM 1 cells) by interacting with RIPK2 (Kd=2.3 uM).

Crisdesalazine (AAD-2004, AAD2004) is a derivative of aspirin that inhibits microsomal PGE(2) synthase-1 (mPGES-1) activity in response to both LPS-treated BV2 cell with IC50 of 230 nM and recombinant human mPGES-1 protein with IC50 of 249 nM in vitro.

Crizotinib (PF-02341066;PF-2341066) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with Ki of 4 nM.

Cromoglicic acid is a mast cell stabilizer with anti-inflammatory activity that prevents the release of inflammatory chemicals such as histamine, leukotrienes from mast cells.

CS3 is a potent, selective cIAP1 and cIAP2 inhibitor with IC50 of 16 nM and 85 nM respectively, shows no significant activity against XIAP (IC50>34 uM)..

CS-3150 (Esaxerenone, XL-550) is a highly potent, selective and orally active non-steroidal mineralocorticoid receptor antagonist with IC50 of 9.4 nM; displays >1,000-fold selectivity over other steroid hormone receptors, glucocorticoid receptor, androgen receptor and progesterone receptor; inhibits aldosterone-induced transcriptional activation of human mineralocorticoid receptor with IC50 of 3.7 nM, shows superior potency to that of spironolactone and eplerenone; suppresses aldosterone-induced decrease in urinary Na(+)/K(+) ratio, inhibits blood pressure elevation induced by DOCA/salt-loading in rats.

CS-526 (AKU 517.

CSF1R-IN-22 is a potent, cellular active and orally bioavailable CSF1R inhibitor with IC50 of 0.5 nM, displays 120-fold selectivity over c-Kit; has improved metabolic stability and Caco2 permeability.

CSIC E379 is a potent, selective uncoupling proteins UCP1/UCP2 inhibitor with EC50 of 20 uM/30 uM, respectively.

CSLP37 (RIPK2 inhibitor CSLP37) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 16.3 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling.

CSLP43 (RIPK2 inhibitor CSLP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling.

CSN5i-3 (CSN5 inhibitor 3) is a potent, selective and orally available inhibitor of CSN5 with IC50 of 5.8 nM, the proteolytic subunit of COP9 signalosome (CSN).

CSRM617 (CSRM-617) is a small-molecule inhibitor of the transcription factor ONECUT2 (OC2) with Kd of 7.43 uM in SPR assays, binds to OC2-HOX domain directly.

CSRM617 hydrochloride (CSRM-617) is a small-molecule inhibitor of the transcription factor ONECUT2 (OC2) with Kd of 7.43 uM in SPR assays, binds to OC2-HOX domain directly.

CT-707 (Conteltinib) is a novel multikinase inhibitor targeting FAK (IC50=1.6 nM), ALK and Pyk2, exerts synergistic antitumor effects against hepatocellular carcinoma in vitro and in vivo.

CTA056 (CTA 056) is a potent, selective inhibitor of interleukin-2-inducible T-cell kinase (Itk) with IC50 of ~100 nM, also inhibits Btk (IC50=400 nM), but shows no significant inhibition for Etk (BMX kinase, IC50=5 uM).

CTA095 (CTA-095) is a potent Etk (BMX) and Src dual inhibitor with IC50 of 60 and 120 nM, respectively, shows no significant inhibition on Btk and Yes at 10 uM.

CTDP-32476 is a potent and selective dopamine transporter (DAT) inhibitor and a competitive inhibitor of cocaine binding to the DAT with Ki of 12 nM.

CTN06 is a potent Etk (BMX) and Btk dual inhibitor with IC50 of 200 and 50 nM, respectively.

CTPB is an anacardic acid derivative, was reported as a selective activator of p300 (KAT3B) HAT activity but not PCAF (KAT2B), which enhanced HAT-dependent transcriptional activation.

CTPI-2 (SLC25A1 inhibitor CTPI-2) is a novel specific SLC25A1 inhibitor with Kd of 3.5 uM, CTPI-2 is synthetic lethal with cisplatin or with EGFR inhibitor co-treatment and restores antitumor responses both in vitro and in vivo; disrupts self-renewal and

CTS-1027 is a potent small molecule inhibitor of MMPs(IC50=0.4 nM/0.6 nM for MMP2/MMP13); >1,000 fold selectivity over MMP1.

CU239 is a novel non-retinoid RPE65 inhibitor that selectively inhibits isomerase activity of RPE65 with IC50 of 6 uM.

CU-3 (DGKα inhibitor CU-3) is a is a novel potent, selective diacylglycerol kinase α (DGKα) inhibitor with IC50 of 0.6 uM, targets the catalytic region, but not the regulatory region.

CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1.

CUR-61414 is a small molecule Hedgehog (Hh) inhibitor that can block elevated Hh signaling activity resulting from oncogenic mutations in Patched-1, binds directly with Smoothened (Ki=44 nM).

Cuspin-1 is a small molecule upregulator of SMN (Survival of Motor Neuron protein) with EC50 of 18 uM.

CVT-12012 is a potent and orally bioavailable stearoyl-coA desaturase (SCD) inhibitor, with IC50s of 38 nM, 6.1 nM for rat microsomal and human HEPG2, respectively.

CWP-232228 is a highly potent small-molecule Wnt/β-catenin signaling inhibitor that targets the β-catenin/Tcf4 interaction in the nucleus.

CX 4338 (CX4338, CX-4338) is a potent, selective CXCR2 inhibitor that selectively inhibits CXCR2-mediated recruitment of β-arrestin-2 with IC50 of 6.3 uM.

CX546 is an AMPA receptor potentiator and GluR activator, binds specifically to the agonist bound non-desensitized receptor.

CX-614 is a positive allosteric modulator of AMPA receptors, shows neuroprotective effects for treatment of Parkinson's disease and Alzheimer's disease.

CXCR2-IN-1 is a central nervous system penetrant CXCR2 antagonists with a pIC50 of 9.3.

CXCR2-IN-68 is a potent, selective, brain penetrant, and orally bioavailable CXCR2 antagonist with pIC50 of 9.0, displays 730-fold selectivity over CXCR1 and >1,900-fold selectivity over all other chemokine receptors.

CXL017 is a small molecule that has selective cytotoxicity toward MDR cancer cell lines in vitro, through inhibition of the sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA) with IC50 of 15 uM.

CYC065 is an orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9) with potential antineoplastic and chemoprotective activities.

CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM.

Cyclapolin 1 is a potent and selective PLK1 inhibitor that promotes loss of centrosome integrity and microtubule nucleating ability apparently through increased accessibility of protein phosphatases.

Cyclapolin 9 is a potent, selective, and ATP-competitive polo-like kinase PLK1 inhibitor with IC50 of 500 nM..

Cyclo(His-Pro) is a cyclic dipeptide structurally related to tyreotropin-releasing hormone.

Cyclocreatine Phosphate (AM 285) is an analog of the creatine kinase CKMT1 substrate creatine and inhibitor of the creatine biosynthesis pathway.

Cyclopamine tartrate is a natural steroidal alkaloid that inhibits hedgehog (Hh) signaling with IC50 of 46 nM.

Cyclophilin inhibitor C31 (SMCypI C31) is a small-molecule cyclophilin (CypA) inhibitor (SMCypI) with PPIase inhibition IC50 of 0.1 uM, displays anti-HCV activity (HCV Gt1b replicon EC50=0.4 uM) and disrupts the CypA-NS5A interaction.

Cyclosporin A-Derivative 1 (Free base) is a crystalline intermediate derived from the opening of cyclosporin A extracted from patent WO 2013167703 A1. Cyclosporin A is an immunosuppressive agent which can bind to the cyclophilin and inhibit calcineurin.

Cyclothiazide (Doburil) is a positive allosteric modulator of the AMPA and kainate receptors that potentiates AMPA-mediated glutamate currents.

CYD-1-79 is a potent, selective 5-HT2C receptor positive allosteric modulator (PAM), potentiates 5-HT-evoked intracellular calcium release in cells stably expressing the human 5-HT2CR but not the 5-HT2AR cells..

CYD-2-11 is a novel potent, selective Bax agonist that targets the structural pocket proximal to S184 in the C-terminal region of Bax (Ki=34.1 nM).

CYH33 (CYH-33) is a novel potent, PI3Kα-selective inhibitor with IC50 of 5.9 nM/598 nM/ 78.7 nM/225 nM aginst class I PI3K isoform α/β/δ/γ, respectively.

CYH33 (CYH-33) is a novel potent, PI3Kα-selective inhibitor with IC50 of 5.9 nM/598 nM/ 78.7 nM/225 nM aginst class I PI3K isoform α/β/δ/γ, respectively.

CYP11B1-IN-25 is a selective, potent 11β-hydroxylase (CYP11B1) inhibitor with IC50 of 2 nM, displays 14-fold selectivity over CYP11B2.

CYT997 is a potent microtubule polymerization inhibitor with IC50 of 10-100 nM in cancer cell lines. Phase 1/2.

CZh226 hydrochloride (CZh-226) is a potent, selective inhibitor of p21-activated kinase 4 (PAK4) with Ki of 9 nM, displays 346-fold selectivity over PAK-1.

CZh226 hydrochloride (CZh-226) is a potent, selective inhibitor of p21-activated kinase 4 (PAK4) with Ki of 9 nM, displays 346-fold selectivity over PAK-1.

D-(+)-Cellobiose is a substrate of β-glucosidase.

D-(+)-Trehalose dihydrate can be used as a food ingredient and pharmaceutical excipient.

D,L-Buthionine-(S,R)-sulfoximine is a potent inhibitor of glutamylcysteine synthetase biosynthesis.

D13-9001 (D 13-9001) is a small molecule, MexAB-OprM specific efflux pump inhibitor with good potency in vitro (MPC 2 ug/mL) and displays excellent activity in vivo in a rat pneumonia model of P. aeruginosa..

D156844 is a potent SMN2 inducer and DcpS inhibitor.

D159153 (D-159153) is a novel potent, allosteric inhibitor of PDE4 with cellular IC50 of 28.5 and 6.6 nM for PDE4B1 and PDE4D3, respectively..

D-520 is a potent, multifunctional D2/D3 agonist with Ki of 41.8 /0.35 nM, modulates aggregation of alpha-synuclein (αSN) and reduces toxicity of preformed aggregates of αSN.

D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC50s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and d

D609 is a selective competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor (Ki = 6.4 μM); antiviral and antitumor agent.

D715-2441 (D 715-2441) is a novel antiviral compound that interferes with the conserved cap-binding domain of the PB2 protein, exhibits potent antiviral activity against influenza A viruses (IAVs) with IC50 of 1.7-4.4 uM.

Dabigatran etexilate mesylate (BIBR 1048MS) is the orally active prodrug of dabigatran. Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki value of 4.5 nM.

Dactinomycin (also known generically as Actinomycin D ) is the most significant member of actinomycines, which are a class of polypeptide antibiotics isolated from soil bacteria of the genus Streptomyces.

Dafadine A is the first reported small-molecule DAF-9 cytochrome P450 inhibitor that robustly induces dauer formation in in the nematode Caenorhabditis elegans.

Dagrocorat (PF 00251802) is a potent, selective high-affinity dissociated agonist of the glucocorticoid receptor..

Dalcetrapib (JTT-705) is a rhCETP inhibitor with IC50 of 0.2 μM.

Damnacanthal is a highly potent, selective inhibitor of p56 lck tyrosine kinase with IC50 of 17 nM for inhibition of p56lck autophosphorylation.

Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency.

Danicopan (ACH-4471, ACH-0144471) is a highly potent, orally active Factor D inhibitor with Kd of 0.54 nM, inhibits the proteolytic activity of purified Factor D against substrate Factor B in complex with C3b, blocking production of Bb fragment IC50 of 15 nM.

Dansyl amide is a fluorescent dye that is used in biochemistry and chemistry to label substances with the fluorescent dansyl group.

Dantrolene sodium hemiheptahydrate is a skeletal muscle relaxant which acts by blocking muscle contraction beyond the neuromuscular junction. Dantrolene sodium hemiheptahydrate is a inhibitor of calcium channel proteins, inhibiting the release of Ca2+ fro

Dapagliflozin propanediol belongs to the class of orally administered antidiabetic agents designated as sodiumglucose cotransporter 2 (SGLT2) inhibitors.

DAPH-1 (CGP 52411) is a small molecule that directly inhibits prion protein Sup35 prionogenesis with IC50 of 0.58 uM, inhibits and reverses the formation of Aβ42 fibers and reduces their toxicity to neurons in culture.

DAPH-12 is a small molecule that directly inhibits and reverses prion protein Sup35 prionogenesis (IC50=0.18 uM).

Dapoxetine HCl is a short-acting novel selective serotonin reuptake inhibitor(SSRI).

Dapsone, also known as diaminodiphenyl sulfone (DDS), is an antibiotic commonly used in combination with rifampicin and clofazimine for the treatment of leprosy.

Daptomycin is a lipopeptide antibiotic with rapid in vitro bactericidal activity against gram-positive organisms.

Darifenacin is a selective M3 muscarinic receptor antagonist with pKi of 8.9.

Darunavir ethanolate is an HIV protease inhibitor,showed potent activity against COVID-19(SARS-COV-2).

Dasolampanel (NGX426) is an orally bioavailable, competitive antagonist of the AMPA-kainate receptors for the treatment of chronic pain conditions including neuropathic pain and migraine..

Daun02 is a daunorubicin b-galactoside prodrug for use in conjunction.

Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM.